PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for September 20, 2007 Subscribe to this News Feed    
 

Citra Anticoagulants Announces CE Mark Approval for LOXXIT™ Catheter Lock Solution

Citra Anticoagulants, Inc. a worldwide distributor of citrate-based anticoagulants received CE Mark approval for LOXXIT™ Catheter Lock Solution.

Braintree, MA (PRWEB) September 20, 2007 -- Citra Anticoagulants, Inc. a leading, developer and worldwide distributor of citrate-based anticoagulants reported today that it has received CE Mark approval for LOXXIT™ Catheter Lock Solution. This regulatory achievement clears the way for Citra to market and distribute this product throughout the European Union and in other countries that recognize the CE Mark.

LOXXIT™ Catheter Lock Solution, 46.7% Trisodium Citrate Dihydrate, 5 mL, is a sterile solution that prevents the coagulation of blood, eliminates the growth of microorganisms in any type of intravenous catheter, and prevents biofilm formation because it eliminates the growth of bacteria, yeast, and fungi in the catheter lumen. LOXXIT™ is a preventive-action product and was designed to prevent problems from occurring rather than treating problems that have occurred.

In September 2007, Citra signed an exclusive Marketing Services Agreement with H.A.C. Pharma which appoints H.A.C. Pharma as the sole representative to promote the marketing and sales activities of LOXXIT™ Catheter Lock Solution to distributors in Europe, the Middle East, and Africa.

For more information on LOXXIT™ Catheter Lock Solution, contact H.A.C. Pharma if you are located in Europe, the Middle East, or Africa, or contact Citra Anticoagulants, Inc. for the rest of the world.

About Citra Anticoagulants
Headquartered in Braintree, Massachusetts, 10 minutes outside of Boston, Massachusetts, Citra Anticoagulants, Inc. markets and distributes a multitude of citrate-based anticoagulants to the worldwide medical arena. For more information about Citra and our products, visit our website at www.CitraAnticoagulants.com.

Team Citra embraces the mission to develop and market safe and effective citrate-based anticoagulants for the medical community, while providing outstanding customer service. Citra's products are used in many different applications: from the anticoagulant of choice in the preparation of platelet rich plasma, which is used as an aid in wound healing, to the anticoagulant of choice for the collection of granulocytes which are used to support patients undergoing cancer therapy, and to a superb catheter lock solution where the product functions as an anticoagulant and an antimicrobial agent.

About H.A.C. Pharma
H.A.C. Pharma is headquartered in Caen, France. It is a pharmaceutical marketing company focused on specialty therapeutic areas. The company commercializes drugs, medical devices, and food supplements for medical purposes in France and throughout the world. For more information and how to contact H.A.C. Pharma, visit www.hacpharma.com.

###

OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Ronald H. Lewis, President
Citra Anticoagulants, Inc.
1-781-848-2174
Email us Here
Adrienne Summers
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.